Binimetinib versus chemotherapy in recurrent or persistent low-grade serous ovarian carcinomas

Although not meeting the primary endpoint, binimetinib should be considered a viable treatment for recurrent or persistent low-grade serous ovarian carcinomas.
Although not meeting the primary endpoint, binimetinib should be considered a viable treatment for recurrent or persistent low-grade serous ovarian carcinomas.